These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24339438)

  • 1. Ten years of proteomics in multiple sclerosis.
    Farias AS; Pradella F; Schmitt A; Santos LM; Martins-de-Souza D
    Proteomics; 2014 Mar; 14(4-5):467-80. PubMed ID: 24339438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can proteomics elucidate the complexity of multiple sclerosis?
    Farias AS; Santos LM
    Proteomics Clin Appl; 2015 Oct; 9(9-10):844-7. PubMed ID: 25980360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis.
    Herrero-Herranz E; Pardo LA; Gold R; Linker RA
    Neurobiol Dis; 2008 May; 30(2):162-73. PubMed ID: 18342527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neuronal injury in multiple sclerosis].
    Correale J; Meli F; Ysrraelit C
    Medicina (B Aires); 2006; 66(5):472-85. PubMed ID: 17137182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions.
    Kornek B; Storch MK; Weissert R; Wallstroem E; Stefferl A; Olsson T; Linington C; Schmidbauer M; Lassmann H
    Am J Pathol; 2000 Jul; 157(1):267-76. PubMed ID: 10880396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models.
    Lassmann H
    Exp Neurol; 2010 Sep; 225(1):2-8. PubMed ID: 19840788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.
    Dagley LF; Emili A; Purcell AW
    Proteomics Clin Appl; 2013 Jan; 7(1-2):91-108. PubMed ID: 23112123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
    Forte M; Gold BG; Marracci G; Chaudhary P; Basso E; Johnsen D; Yu X; Fowlkes J; Rahder M; Stem K; Bernardi P; Bourdette D
    Proc Natl Acad Sci U S A; 2007 May; 104(18):7558-63. PubMed ID: 17463082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The experimental autoimmune encephalomyelitis model for proteomic biomarker studies: from rat to human.
    Rosenling T; Attali A; Luider TM; Bischoff R
    Clin Chim Acta; 2011 May; 412(11-12):812-22. PubMed ID: 21333641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.
    Salvisberg C; Tajouri N; Hainard A; Burkhard PR; Lalive PH; Turck N
    Proteomics Clin Appl; 2014 Apr; 8(3-4):185-94. PubMed ID: 24488530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.
    Gresle MM; Shaw G; Jarrott B; Alexandrou EN; Friedhuber A; Kilpatrick TJ; Butzkueven H
    J Neurosci Res; 2008 Dec; 86(16):3548-55. PubMed ID: 18709652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis.
    Oveland E; Ahmad I; Lereim RR; Kroksveen AC; Barsnes H; Guldbrandsen A; Myhr KM; Bø L; Berven FS; Wergeland S
    Sci Rep; 2021 Mar; 11(1):7174. PubMed ID: 33785790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurodegeneration in autoimmune CNS inflammation.
    Herz J; Zipp F; Siffrin V
    Exp Neurol; 2010 Sep; 225(1):9-17. PubMed ID: 19961850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis.
    Harris VK; Donelan N; Yan QJ; Clark K; Touray A; Rammal M; Sadiq SA
    Mult Scler; 2013 Oct; 19(11):1462-72. PubMed ID: 23439582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics technologies for biomarker discovery in multiple sclerosis.
    Singh V; Hintzen RQ; Luider TM; Stoop MP
    J Neuroimmunol; 2012 Jul; 248(1-2):40-7. PubMed ID: 22129845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New findings and old controversies in the research of multiple sclerosis and its model experimental autoimmune encephalomyelitis.
    Aharoni R
    Expert Rev Clin Immunol; 2013 May; 9(5):423-40. PubMed ID: 23634737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic targets for axonal degeneration in multiple sclerosis.
    Petratos S; Azari MF; Ozturk E; Papadopoulos R; Bernard CC
    J Neuropathol Exp Neurol; 2010 Apr; 69(4):323-34. PubMed ID: 20448478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.
    Eltayeb S; Berg AL; Lassmann H; Wallström E; Nilsson M; Olsson T; Ericsson-Dahlstrand A; Sunnemark D
    J Neuroinflammation; 2007 May; 4():14. PubMed ID: 17484785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination.
    Merkler D; Ernsting T; Kerschensteiner M; Brück W; Stadelmann C
    Brain; 2006 Aug; 129(Pt 8):1972-83. PubMed ID: 16714315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis.
    Wolswijk G; Balesar R
    Brain; 2003 Jul; 126(Pt 7):1638-49. PubMed ID: 12805111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.